Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans

• Published in: Biology of blood and marrow transplantation Vol. 16; no. 9; pp. 1245 - 1256
• Main Authors: Jensen, Michael C., Popplewell, Leslie, Cooper, Laurence J., DiGiusto, David, Kalos, Michael, Ostberg, Julie R., Forman, Stephen J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2010
• Subjects: Adoptive therapy; Adoptive Transfer - methods; Antigens, CD19 - biosynthesis; Antigens, CD19 - genetics; Antigens, CD19 - immunology; Antigens, CD20 - biosynthesis; Antigens, CD20 - genetics; Antigens, CD20 - immunology; Cellular immunotherapy; Clinical trial; Hematology, Oncology and Palliative Medicine; Humans; Immune Tolerance; Lymphoma, B-Cell - immunology; Lymphoma, B-Cell - therapy; Lymphoma, Follicular - immunology; Lymphoma, Follicular - therapy; Lymphoma, Large B-Cell, Diffuse - immunology; Lymphoma, Large B-Cell, Diffuse - therapy; Receptors, Antigen, T-Cell - biosynthesis; Receptors, Antigen, T-Cell - genetics; Receptors, Antigen, T-Cell - immunology; T lymphocyte; T-Lymphocytes, Cytotoxic - immunology; T-Lymphocytes, Cytotoxic - physiology; T-Lymphocytes, Cytotoxic - transplantation; Transfection; Transgenes - immunology; Clinical trial; Cellular immunotherapy; T lymphocyte; Adoptive therapy

Immunotherapeutic ablation of lymphoma is a conceptually attractive treatment strategy that is the subject of intense translational research. Cytotoxic T lymphocytes (CTLs) that are genetically modified to express CD19- or CD20-specific, single-chain antibody–derived chimeric antigen receptors (CARs...